SML0650

Risedronate sodium

≥97% (HPLC)

• 동의어(들): P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
• 실험식(Hill 표기법): C₇H₁₀NO₇P₂ · Na
• CAS Number: 115436-72-1
• Molecular Weight: 305.09
• UNSPSC 코드: 41106300
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥97% (HPLC)
• 양식: powder
• 색상: white to beige
• solubility: H₂O: 5 mg/mL, clear (warmed)
• 저장 온도: room temp
• SMILES string: [Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
• InChI: 1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
• InChI key: DRFDPXKCEWYIAW-UHFFFAOYSA-M

설명

생화학적/생리학적 작용

Risedronate sodium is a bisphosphonate bone resorption inhibitor.

Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H302 + H312 + H332
• 예방조치 성명서: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable